세계의 임상시험 환자 모집 서비스 시장 규모, 점유율, 동향 분석 : 서비스별, 상별, 치료 영역별, 연령층별, 지역별, 부문별 예측(2025-2033년)

Clinical Trial Patient Recruitment Services Market Summary

The global clinical trial patient recruitment services market size was valued at USD 10.99 billion in 2024 and is projected to reach USD 22.85 billion by 2033, growing at a CAGR of 8.72% from 2025 to 2033. The market growth is driven by an increasing number of clinical trials for rare & chronic diseases, and increasing use of recruitment technologies, which enhance the processes of patient identification & engagement.

Some other factors contributing to market growth are the growing complexity of clinical trial protocols and the increasing funding for clinical research activities, which is encouraging for high R&D spending and outsourcing trends. In addition, emphasis on patient diversity, decentralized trials, and using AI-based analytics to improve enrollment efficiency further drives the market growth.

Many pharmaceutical companies outsource various tasks, from basic research to late-stage manufacturing. The contract research organizations (CROs) play a crucial role in patient recruitment as intermediaries between sponsors & study participants. Most CROs utilize their resources, expertise, and networks to identify and enroll candidates for clinical trials. These CROs collaborate with sponsors to understand the study requirements & to develop effective recruitment strategies. In addition, most clinical trial patient recruitment service providers implement strong data security measures and comply with strict privacy regulations to protect the participants' information. Also, outsourcing clinical trial patient recruitment offers numerous benefits for pharmaceutical companies by utilizing the expertise of specialized recruitment services. This supports companies to save time, money, & resources while ensuring the timely recruitment of participants, further boosting efficiency and improving participant diversity.

According to a May 2024 report, Merck & Co. recorded an R&D expenditure of USD 30.5 billion in 2023, demonstrating its strong commitment to advancing innovation and drug development. This surge in R&D activities has resulted in a growing number of clinical trials worldwide, intensifying the need for efficient patient recruitment solutions.

Moreover, regulatory bodies like the FDA, EMA, and MHRA are implementing reforms emphasizing patient diversity, transparency, and faster trial approvals. For instance, in September 2025, the European Commission, Heads of Medicines Agencies (HMA), and EMA introduced new clinical trial targets under the Accelerating Clinical Trials (ACT) EU initiative to accelerate approvals, enhance multinational participation, and promote patient diversity. These reforms encourage inclusion of underrepresented populations and multinational participation, necessitating broader patient outreach capabilities. Recruitment service providers leverage global networks and digital tools to identify diverse patient groups that meet new regulatory expectations. As a result, these evolving frameworks enhance the importance of specialized recruitment services capable of meeting compliance, diversity, and enrollment speed requirements, further propelling market demand.

In addition, digital technology such as artificial intelligence (AI), electronic health records (EHR), and predictive analytics has made it possible to develop a strong patient recruiting strategy. In contrast, drug manufacturers have historically utilized TV commercials, radio, and print media for patient recruitment. These tools enable real-time patient identification, enhance pre-screening accuracy, and reduce manual workloads. AI-driven recruitment platforms can automatically match patients to trials based on clinical history and eligibility criteria, minimizing human error and improving speed. For instance, in June 2024, TrialX launched an AI-powered Clinical Trial Finder that utilizes NLP and machine learning to match patient data with eligibility criteria, providing personalized trial options by relevance and location, enhancing accessibility and accelerating recruitment efficiency. Digital engagement channels like telehealth and wearable monitoring enhance patient participation and retention. Thus, pharmaceutical and biotech companies increasingly adopt these technologies to reduce costs and shorten trial timelines.

Global Clinical Trial Patient Recruitment Services Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global clinical trial patient recruitment services market based on service, phase, therapeutic area, age group and region:

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Patient recruitment & registry services
• Patient retention services
• Others
• Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Phase I
• Phase II
• Phase III
• Phase IV
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Respiratory diseases
• Pain and anesthesia
• Oncology
• Central nervous system
• Cardiovascular
• Endocrine
• Anti-infective
• Others
• Age Group Outlook (Revenue, USD Million, 2021 - 2033)
• Child (birth-17 years)
• Adult (18 - 64 years)
• Older adults (65 years+)
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Phase
  • 1.2.3. Therapeutic Area
  • 1.2.4. Age Group
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Clinical Trial Patient Recruitment Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. High R&D Spending of Pharmaceutical Companies
    • 3.2.1.2. Increase In Number of Global Clinical Trials
    • 3.2.1.3. Adoption Of Digital Clinical Trials
    • 3.2.1.4. Increase In Offshoring of Clinical Trials in Emerging Market
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack Of Awareness Towards Clinical Trials
    • 3.2.2.2. Lack Of Adequate Regulatory Framework For Conducting Clinical Trials In Some Countries
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Clinical Trial Patient Recruitment Services Market: Service Estimates & Trend Analysis

• 4.1. Clinical Trial Patient Recruitment Services Market, By Service: Segment Dashboard
• 4.2. Clinical Trial Patient Recruitment Services Market, By Service: Movement Analysis
• 4.3. Clinical Trial Patient Recruitment Services Market Estimates & Forecasts, By Service, 2021 - 2033
• 4.4. Patient Recruitment & Registry Services
  • 4.4.1. Patient Recruitment & Registry Services Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Patient Retention Services
  • 4.5.1. Patient Retention Services Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Clinical Trial Patient Recruitment Services Market: Phase Estimates & Trend Analysis

• 5.1. Clinical Trial Patient Recruitment Services Market, By Phase: Segment Dashboard
• 5.2. Clinical Trial Patient Recruitment Services Market, By Phase: Movement Analysis
• 5.3. Clinical Trial Patient Recruitment Services Market Estimates & Forecasts, By Phase, 2021 - 2033
• 5.4. Phase I
  • 5.4.1. Phase I Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Phase II
  • 5.5.1. Phase II Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Phase III
  • 5.6.1. Phase III Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Phase IV
  • 5.7.1. Phase IV Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Clinical Trial Patient Recruitment Services Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Clinical Trial Patient Recruitment Services Market, By Therapeutic Area: Segment Dashboard
• 6.2. Clinical Trial Patient Recruitment Services Market, By Therapeutic Area: Movement Analysis
• 6.3. Clinical Trial Patient Recruitment Services Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033
• 6.4. Respiratory Diseases
  • 6.4.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Pain and Anesthesia
  • 6.5.1. Pain and Anesthesia Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Oncology
  • 6.6.1. Oncology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Central Nervous System
  • 6.7.1. Central Nervous System Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Cardiovascular
  • 6.8.1. Cardiovascular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Endocrine
  • 6.9.1. Endocrine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.10. Anti-infective
  • 6.10.1. Anti-infective Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.11. Others
  • 6.11.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Clinical Trial Patient Recruitment Services Market: Age Group Estimates & Trend Analysis

• 7.1. Clinical Trial Patient Recruitment Services Market, By Age Group: Segment Dashboard
• 7.2. Clinical Trial Patient Recruitment Services Market, By Age Group: Movement Analysis
• 7.3. Clinical Trial Patient Recruitment Services Market Estimates & Forecasts, By Age Group, 2021 - 2033
• 7.4. Child (birth-17 years)
  • 7.4.1. Child (birth-17 years) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Adult (18 - 64 years)
  • 7.5.1. Adult (18 - 64 years) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Older Adults (65 years+)
  • 7.6.1. Older Adults (65 years+) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Clinical Trial Patient Recruitment Services Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2024 & 2030
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Thailand
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. South Korea
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Australia
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Oman
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Qatar
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Clara Health
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Antidote
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. BBK Worldwide
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Clariness
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Clinical Site Services (CCSi)
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Worldwide Clinical Trials
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Thermo Fisher Scientific Inc. (PPD Inc.)
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. IQVIA Inc
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Veristat
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Elligo Health Research
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. AutoCruitment
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. MMG (Omnicom Health Group)
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Praxis
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. Science37
    • 9.3.14.1. Company Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. StudyKik
    • 9.3.15.1. Company Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Service Benchmarking
    • 9.3.15.4. Strategic Initiatives